Molecular Metabolism (Feb 2020)

Continuous glucose monitoring reveals glycemic variability and hypoglycemia after vertical sleeve gastrectomy in rats

  • Simon S. Evers,
  • Ki-Suk Kim,
  • Nadejda Bozadjieva,
  • Alfor G. Lewis,
  • Diana Farris,
  • Matthew J. Sorensen,
  • Youngsoo Kim,
  • Steven E. Whitesall,
  • Robert T. Kennedy,
  • Daniel E. Michele,
  • Randy J. Seeley,
  • Darleen A. Sandoval

Journal volume & issue
Vol. 32
pp. 148 – 159

Abstract

Read online

Objective: Post–bariatric surgery hypoglycemia (PBH) is defined as the presence of neuroglycopenic symptoms accompanied by postprandial hypoglycemia in bariatric surgery patients. Recent clinical studies using continuous glucose monitoring (CGM) technology revealed that PBH is more frequently observed in vertical sleeve gastrectomy (VSG) patients than previously recognized. PBH cannot be alleviated by current medication. Therefore, a model system to investigate the mechanism and treatment is required. Methods: We used CGM in a rat model of VSG and monitored the occurrence of glycemic variability and hypoglycemia in various meal conditions for 4 weeks after surgery. Another cohort of VSG rats with CGM was used to investigate whether the blockade of glucagon-like peptide-1 receptor (GLP-1R) signaling alleviates these symptoms. A mouse VSG model was used to investigate whether the impaired glucose counterregulatory system causes postprandial hypoglycemia. Results: Like in humans, rats have increased glycemic variability and hypoglycemia after VSG. Postprandial hypoglycemia was specifically detected after liquid versus solid meals. Further, the blockade of GLP-1R signaling raises the glucose nadir but does not affect glycemic variability. Conclusions: Rat bariatric surgery duplicates many features of human post–bariatric surgery hypoglycemia including postprandial hypoglycemia and glycemic variability, while blockade of GLP-1R signaling prevents hypoglycemia but not the variability. Keywords: Continuous glucose monitoring, Vertical sleeve gastrectomy, Post–bariatric surgery hypoglycemia, Glycemic variability, Exendin 9-39, Glucagon-like peptide-1 receptor